PDL1V ADC Plus Pembrolizumab Achieves 50% ORR in PD-L1+ r/mHNSCC

In a phase 1 trial cohort of 14 PD-L1+ (CPS ≥1) patients with recurrent or metastatic HNSCC, the combination of PDL1V and pembrolizumab yielded a 50% ORR, including a 21.4% complete response rate. Common treatment-related adverse events were fatigue, nausea (50%), and grade ≥3 diarrhea (14.3%). Compared to pembrolizumab monotherapy (KEYNOTE-048 trial) ORR of 17% and CR of 5% makes this combo look even better!